Standard BioTools (STU:FLB) Beginning Cash Position: €232.51 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:FLB Standard BioTools Inc STU:FLB
41 GF Score
Price €0.69
GF Value €0.60
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools Beginning Cash Position?

Standard BioTools STU:FLB -0.72% 41 Beginning Cash Position is €232.51 Mil as of Jun. 2026. GuruFocus rates STU:FLB with a GF Score™ of 41/100 and a GF Value™ of €0.60 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Standard BioTools's Beginning Cash Position for the quarter that ended in Jun. 2026 was €232.51 Mil.

Standard BioTools's quarterly Beginning Cash Position declined from Dec. 2025 (€112.73 Mil) to Mar. 2026 (€106.65 Mil) but then increased from Mar. 2026 (€106.65 Mil) to Jun. 2026 (€232.51 Mil).

Standard BioTools's annual Beginning Cash Position declined from Dec. 2023 (€75.49 Mil) to Dec. 2024 (€50.14 Mil) but then increased from Dec. 2024 (€50.14 Mil) to Dec. 2025 (€144.17 Mil).

Standard BioTools Beginning Cash Position Related Terms

Standard BioTools Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Standard BioTools's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools Beginning Cash Position Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.54 27.82 75.49 50.14 144.17

Standard BioTools Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.06 137.35 112.73 106.65 232.51
STU:FLB
41GF Score
Standard BioTools Inc STU:FLB
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €232.51 Mil mean?
Standard BioTools (STU:FLB) has a Beginning Cash Position of €232.51 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Standard BioTools and its competitors.
Is Standard BioTools' Beginning Cash Position too high?
Standard BioTools' current Beginning Cash Position is €232.51 Mil. Overall, Standard BioTools has a GF Score™ of 41/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Beginning Cash Position compare to CV and ELMD?
Standard BioTools' Beginning Cash Position of €232.51 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Standard BioTools and its competitors. Standard BioTools's current Beginning Cash Position is €232.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.60, compared to a current price of €0.69 — trading 14.2% above its estimated fair value. The current Beginning Cash Position is €232.51 Mil. Standard BioTools' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Beginning Cash Position is €232.51 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard BioTools (STU:FLB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued. The current stock price of €0.69 is trading 14.2% above its estimated GF Value™ of €0.60. GuruFocus considers Standard BioTools to be Modestly Overvalued.

Key valuation signals for STU:FLB:

  • Beginning Cash Position: €232.51 Mil
  • GF Value™: €0.60 vs. price of €0.69 (14.2% above fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Standard BioTools Business Description

Other Exchanges LAB:USA
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
41GF Score

Get the complete analysis for STU:FLB

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.60
GF Value